Campath
Mendelian Susceptibility to Mycobacterial Disease
Paul SzabolcsPhase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Mendelian Susceptibility to Mycobacterial Disease cohort.
Same molecule, other indications
Campath is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →